French drugmaker Sanofi-Aventis hopes to reach a takeover deal that would value U.S. target Genzyme (GENZ.O) at around $76 per share, or some $20 billion, the French daily newspaper Le Figaro said on Friday. The total figure would include a cash component of $70 to $71 combined with an earn-out known as a contingent value right (CVR), the article said, citing unnamed sources in the French camp. Sanofi could not immediately be reached to comment on the report.
Source
